Syngene International Limited vs Indegene Limited
An objective side-by-side of SYNGENE and INDGN, both in Healthcare Research, Analytics & Technology: valuation, profitability, growth, balance sheet, ownership and share-price performance. Where one number is clearly better on its own terms (lower P/E, higher ROE), it is shaded. That is a description, not a recommendation.
Prices as of 2026-10-16 close
Latest results: SYNGENE Jun 2026 · INDGN Jun 2026
At a glance
- Syngene International Limited is the larger company by market value, about 1.1 times the size of Indegene Limited.
- On trailing earnings, Indegene Limited trades at the lower P/E (35.9 against 70.3).
- Indegene Limited earns the higher return on equity (12.8% against 4.6%).
- Over three years Indegene Limited has grown profits faster (16% a year against -7%).
- Over the past year the share prices returned -40.7% (SYNGENE) and +7.5% (INDGN).
| Metric | Syngene International SYNGENE |
Indegene INDGN |
|---|---|---|
| Size and price | ||
| Market cap | ₹15,541 Cr | ₹14,408 Cr |
| Share price | ₹386.10 | ₹598.30 |
| Valuation | ||
| P/E | 70.32 | 35.91 |
| P/B | 3.21 | 4.59 |
| EV/EBITDA | 19.93 | 22.80 |
| PEG | — | 2.24 |
| Dividend yield | 0.3% | 0.3% |
| Profitability | ||
| ROE | 4.6% | 12.8% |
| ROCE | 10.0% | 19.0% |
| Operating margin | 22.3% | 16.7% |
| Sales (TTM) | ₹3,600 Cr | ₹3,812 Cr |
| Net profit (TTM) | ₹221 Cr | ₹401 Cr |
| Growth | ||
| Latest quarter sales YoY | -15.8% | +39.7% |
| Latest quarter profit YoY | -110.4% | -0.2% |
| Sales CAGR 3Y | +5.0% | +15.0% |
| Profit CAGR 3Y | -7.0% | +16.0% |
| Sales CAGR 5Y | +11.0% | +29.0% |
| Profit CAGR 5Y | +0.0% | +23.0% |
| Financial strength | ||
| Debt/Equity | 0.09 | 0.05 |
| Interest cover | 9.57 | 25.80 |
| Ownership | ||
| Promoter holding | 52.6% | — |
| Promoter change (4 qtrs) | -0.09 pp | — |
| Price performance | ||
| Return 1M | +1.58% | +4.38% |
| Return 3M | -7.51% | +17.11% |
| Return 1Y | -40.72% | +7.48% |
| Return YTD | -40.69% | +14.96% |
| Technical condition | ||
| Technical score | 62 | 63 |
| RS rating (1-99) | 19.00 | 77.00 |
| % vs 200-DMA | -12.81% | +15.21% |
| RSI (14) | 55.41 | 54.17 |
| % from 52-week high | -43.13% | -4.58% |
